In this article, guest author Jeffrey S. Barkin, MD, describes an approach to reading journal literature designed to derive the most useful information in the least amount of time.
Read More
You won’t get very far into any journal before you start reading about statistical significance, and its close sibling, 95% confidence intervals. But what do these terms mean, and how do they help us draw conclusions about studies?
Read More
Dr. Oransky, as Deputy Editor of The Scientist, I know that you spend a great deal of time looking at medical statistics, and you do an excellent job of making these concepts understandable in your column in CNS News, Statistically Speaking.
Read More
Vitamin E, recommended variously for preventing cardiovascular disease, Alzheimer’s disease, and tardive dyskinesia, has taken quite a drubbing in recent years. Recent results from Harvard’s Women's Health Study have put another nail in its coffin.
Read More
Guanfacine is an alpha-2 agonists approved for the treatment of hypertension, but commonly prescribed for posttraumatic stress disorder. Like clonidine, another alpha-2 agonist, guanfacine is believed to decrease norepinephrine release from noradrenergic neurons during states of heightened arousal.
Read More
We have no effective treatment for severe amphetamine dependence. Now, a study from Finland points to an obvious candidate treatment for those meeting DSMIV criteria for intravenous amphetamine dependence. Patients were randomly assigned to Abilify (aripiprazole--15 mg/day), Concerta (methylphenidate controlled release--54 mg/day) or placebo for 20 weeks.
Read More
Recently, the FDA approved the Amplichip CYP450 Test (from Roche Diagnostics), which is a device allowing laboratories to quickly find out whether your patient metabolizes drugs too slowly or too quickly.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
